Available
Project number:
2025_43
Start date:
October 2025
Project themes:
Main supervisor:
Dr, Professor in Basic and Clinical Neuroscience
Co-supervisor:
Additional Information:
Data-driven Dementia Treatment Adoption
Background: The first disease-modifying drugs for Alzheimer’s Disease has been licensed in the USA and UK, but is not yet available for wide use due to high cost1 and high risk of adverse outcomes like Amyloid-related Imaging Abnormalities (ARIAs)2. While there are millions of patients at risk for Alzheimer’s Disease, it not currently known which patients would benefit most for the treatment. Data-driven risk profiling is needed to make these treatments affordable and safe.
Novelty & Importance: This project is part of a long-term partnership between Kings College London and a major international private London hospital. The unit will be one of the only units in the United Kingdom (and Europe) with access to these treatments.
Aims & Objectives: Use data and detailed biomarker investigations and imaging to determine benefits and risk of treatments of patients with mild dementia.
Clinicians only: Applicant must be a post-MRCP doctor and able to work part-time as a neurology-registrar-level at a major international private London hospital for 20 hours per week. Individuals must have good communication skills for handling complex medical situations in an international healthcare setting.
References:
MHRA, Lecanemab licensed for adult patients in the early stages of Alzheimer’s disease https://www.gov.uk/government/news/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21.
We are now accepting applications for 1 October 2025
How to apply
Candidates should possess or be expected to achieve a 1st or upper 2nd class degree in a relevant subject including the biosciences, computer science, mathematics, statistics, data science, chemistry, physics, and be enthusiastic about combining their expertise with other disciplines in the field of healthcare.
Important information for International Students:
It is the responsibility of the student to apply for their Student Visa. Please note that the EPSRC DRIVE-Health studentship does not cover the visa application fees or the Immigration Health Surcharge (IHS) required for access to the National Health Service. The IHS is mandatory for anyone entering the UK on a Student Visa and is currently £776 per year for each year of study. Further detail can be found under the International Students tab below.
Next Steps
- Applications submitted by the closing date of Thursday 6 February 2025 will be considered by the CDT. We will contact shortlisted applicants with information about this part of the recruitment process.
- Candidates will be invited to attend an interview. Interviews are projected to take place in April 2025.
- Project selection will be through a panel interview chaired by either Professor Richard Dobson and Professor Vasa Curcin (CDT Directors) followed by informal discussion with prospective supervisors.
- If you have any questions related to the specific project you are applying for, please contact the main supervisor of the project directly.
For any other questions about the recruitment process, please email us at